Table 4.
In-hospital treatment and outcome in patients with and without prolonged QTc on admission.
| QTc ≤ 480 (n = 562) |
QTc > 480 (n = 61) |
p-Value | |
|---|---|---|---|
| Tocilizumab | 94 (16.7) | 11 (18.0) | 0.80 |
| No hydroxychloroquine or azithromycin | 9 (1.6) | 7 (11.5) | <0.001 |
| Hydroxychloroquine | 15 (2.7) | 1 (1.6) | |
| Azithromycin | 7 (1.2) | 3 (4.9) | |
| Hydroxychloroquine + Azithromycin | 531 (94.5) | 50 (82.0) | |
| Oxygen support | 337 (60.0) | 40 (65.6) | 0.12 |
| High Flow Nasal Cannula | 9 (1.6) | 1 (1.6) | |
| Non-invasive ventilation | 27 (4.8) | 3 (4.9) | |
| Intubation and invasive ventilation | 36 (6.4) | 8 (13.1) | |
| QTc prolongation during hospitalization | 148 (68.2) | 20 (71.4) | 0.73 |
| Longest QTc duration, milliseconds | 455.8 ± 40.5 | 536.5 ± 47.8 | <0.001 |
| Length of hospitalization, days | 10 (5–19) | 10 (3–23) | 0.68 |
| Death | 49 (8.7) | 25 (41.0) | <0.001 |
Results are expressed as mean ± standard deviation, median and (interquartile range) or number and (percentage).